Printer Friendly

PFIZER HAS RECEIVED AN 'APPROVABLE LETTER' FOR DIFLUCAN FOR TREATMENT OF VAGINAL CANDIDIASIS

 NEW YORK, Sept. 27 /PRNewswire/ -- Pfizer Inc (NYSE: PFE) confirmed today that it has received an "approvable letter" from the U.S. Food and Drug Administration for the use of Diflucan(A) (fluconazole) in the treatment of vaginal candidiasis. The meaning of such a letter is that FDA and Pfizer will begin discussions of final labeling.
 Diflucan, in both oral and injectable dosage forms, was launched in the U.S. in April 1990 for the treatment of oral and esophageal candidiasis, serious systemic candida infections and cryptococcal meningitis. The new drug application for its use in vaginal candidiasis was filed in December 1992.
 Pfizer Inc is a research-based, diversified health care company with global operations. The company reported sales of approximately $7.23 billion for 1992.
 (A) Diflucan is a registered U.S. trademark.
 -0- 9/27/93
 /CONTACT: Andy McCormick of Pfizer, 212-573-1226/
 (PFE)


CO: Pfizer Inc ST: New York IN: MTC SU:

LG -- NY080 -- 6025 09/27/93 15:13 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 27, 1993
Words:163
Previous Article:SARATOGA BRANDS SIGNS LETTER OF INTENT TO ACQUIRE DIXIE BRANDS; PLANS $2.5 MILLION FINANCING
Next Article:WASHINGTON GAS MEDIUM-TERM NOTES RAISED TO 'AA-' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters